Dr. Heather Sandison
speaker
565 appearances
1 recordings
1 series
first heard Jul 2026
last heard 2 Jul
Dr. Heather Sandison’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.
Appearances
And so unfortunately right now we're kind of stuck in this spot where we have all these medications, all this money going towards this amyloid hypothesis.
And these monoclonal antibodies are now available.
Um, Casunla, Lecembi are on the market or leucanimab, um, ajuhelm adicanimab has been taken off the market.
It it was more risky and less effective than the other two that are available now.
The issue is that just in April, April 16th, I believe, of twenty twenty six, there was a Cochrane Review article.
This is a meta-analysis and a large review of all of the data on the monoclonal antibodies, and the author's conclusions were
Blend.
Essentially these don't work.
They're very expensive with high risk of brain bleeding, brain swelling, and we need to pursue a different mechanism of action.
Th it just this doesn't work to go after amyloid.
We're quite good at getting rid of amyloid, but that does not equate to a meaningful benefit cognitively.
Енсо, вот виду с alternв, the hopeful side of this.
Is that much of this is actually within our control.
We don't have to wait for the next medication to be approved by the FDA.
We don't have to wait for the science to catch up.
We know now, based on multiple studies that include multi-f factorials, basically multimodal interventions that focus on lifestyle, diet, exercise, sleep, stress management.
We consistently get improvements in cognition.
With the monoclonal antibodies, at best what we got was a reduction in the rate of decline.
So with lifestyle interventions, we see an improvement in cognition.
And so this really is up to us.
Showing 101–120 of 565 · page 6 of 29
← Previous
Next →